Whatley SD, Ducamp S, Gouya L, et al. C⁃terminal deletions in the ALAS2 gene lead to gain of function and cause X⁃linked dominant protoporphyria without anemia or iron overload[J]. Am J Hum Genet, 2008, 83(3): 408⁃414. DOI: 10.1016/j.ajhg.2008.08. 003.
[2]
Levy JL, Trelles MA, Levy A, Besson R. Photography in dermatology: comparison between slides and digital imaging[J]. J Cosmet Dermatol, 2003, 2(3⁃4): 131⁃134. DOI: 10.1111/j.1473⁃2130.2004. 00081.x.
[3]
Ducamp S, Schneider⁃Yin X, de Rooij F, et al. Molecular and functional analysis of the C⁃terminal region of human erythroid⁃specific 5⁃aminolevulinic synthase associated with X⁃linked dominant protoporphyria (XLDPP)[J]. Hum Mol Genet, 2013, 22(7): 1280⁃1288. DOI: 10.1093/hmg/dds531.
[4]
Brancaleoni V, Balwani M, Granata F, et al. X⁃chromosomal inactivation directly influences the phenotypic manifestation of X⁃linked protoporphyria [J]. Clin Genet, 2016, 89(1): 20⁃26. DOI: 10.1111/cge.12562.
[5]
Ninomiya Y, Kokunai Y, Tanizaki H, et al. X⁃linked dominant protoporphyria: the first reported Japanese case [J]. J Dermatol, 2016, 43(4): 414⁃418. DOI: 10.1111/1346⁃8138.13101.
[6]
Seager MJ, Whatley SD, Anstey AV, et al. X⁃linked dominant protoporphyria: a new porphyria [J]. Clin Exp Dermatol, 2014, 39(1): 35⁃37. DOI: 10.1111/ced.12202.